Drugmaker Athenex voluntarily files for U.S. Chapter 11 proceedings
14 May 2023
May 14 (Reuters) - Drugmaker Athenex Inc (ATNX.O) and certain of its subsidiaries voluntarily filed for Chapter 11 proceedings, the company said on Sunday.
Athenex reached an agreement with its lenders to move forward with an expedited sale process of its assets, the company said in a statement.
The Buffalo, New York-based company has listed estimated assets and liabilities in the range of $100 million-$500 million, according to a filing with the U.S. Bankruptcy Court for the Southern District of Texas.
The assets to be sold would be across its primary businesses of Athenex Pharmaceutical Division (APD), Orascovery, and Cell Therapy, the company said, adding that it expects the expedited process to be completed by July 1, 2023.
The company said it has sufficient resources to support Athenex Pharma Solutions operations, and fulfill APD customer orders during the sale process.
Our Standards: The Thomson Reuters Trust Principles.
Preview
Source: Reuters
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.